MEP43808A - Polymer conjugates of mutated neublastin - Google Patents
Polymer conjugates of mutated neublastinInfo
- Publication number
- MEP43808A MEP43808A MEP-438/08A MEP43808A MEP43808A ME P43808 A MEP43808 A ME P43808A ME P43808 A MEP43808 A ME P43808A ME P43808 A MEP43808 A ME P43808A
- Authority
- ME
- Montenegro
- Prior art keywords
- polymer conjugates
- mutated neublastin
- neublastin
- polymer
- prolonged
- Prior art date
Links
- 102100026376 Artemin Human genes 0.000 title abstract 3
- 101000785776 Homo sapiens Artemin Proteins 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/356,264 US7442370B2 (en) | 2001-02-01 | 2003-01-31 | Polymer conjugates of mutated neublastin |
PCT/US2004/002763 WO2004069176A2 (en) | 2001-02-01 | 2004-02-02 | Polymer conjugates of mutated neublastin |
YU20050585A RS52910B (en) | 2003-01-31 | 2004-02-02 | POLYMER CONJUGATES OF MUTATED NEUBLASTINE |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP43808A true MEP43808A (en) | 2011-02-10 |
Family
ID=35006489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-438/08A MEP43808A (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
Country Status (27)
Country | Link |
---|---|
EP (3) | EP2301960A3 (sl) |
JP (3) | JP4742025B2 (sl) |
KR (2) | KR101216331B1 (sl) |
CN (2) | CN101166753A (sl) |
AT (1) | ATE478891T1 (sl) |
AU (1) | AU2004209966B9 (sl) |
BR (1) | BRPI0407170A (sl) |
CA (1) | CA2514510C (sl) |
CY (2) | CY1111196T1 (sl) |
DE (1) | DE602004028801D1 (sl) |
DK (2) | DK1594436T3 (sl) |
EA (1) | EA008743B1 (sl) |
ES (2) | ES2450115T3 (sl) |
GE (3) | GEP20135982B (sl) |
HK (1) | HK1085663A1 (sl) |
IL (2) | IL169945A (sl) |
IS (1) | IS7938A (sl) |
ME (1) | MEP43808A (sl) |
MX (1) | MXPA05008168A (sl) |
NO (1) | NO20054025L (sl) |
NZ (2) | NZ541921A (sl) |
PL (1) | PL383683A1 (sl) |
PT (2) | PT1594436E (sl) |
RS (1) | RS52910B (sl) |
SI (2) | SI2246362T1 (sl) |
UA (2) | UA91178C2 (sl) |
ZA (1) | ZA200505707B (sl) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52910B (en) * | 2003-01-31 | 2014-02-28 | Biogen Idec Ma Inc. | POLYMER CONJUGATES OF MUTATED NEUBLASTINE |
DE602005022082D1 (de) * | 2004-08-19 | 2010-08-12 | Biogen Idec Inc | Rückfaltung von proteinen der transforming-growth-factor-beta-familie |
US20140092376A1 (en) * | 2012-10-01 | 2014-04-03 | Momentive Performance Materials, Inc. | Container and method for in-line analysis of protein compositions |
CN110709416A (zh) * | 2017-01-25 | 2020-01-17 | 特沙公司 | TGF-β诱饵受体 |
US20230074641A1 (en) * | 2020-01-27 | 2023-03-09 | Silcotek Corp. | Biopharmaceutical manufacturing process and product |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU187037B (en) | 1983-04-19 | 1985-10-28 | Tibor Sinko | Rope-stretching device |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
CA2092271C (en) | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
KR100587556B1 (ko) | 1996-05-08 | 2006-06-08 | 바이오겐 아이덱 엠에이 인코포레이티드 | 신경 및 신장 증식을 자극하기 위한 RET리간드(RetL) |
KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
ES2297889T3 (es) * | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
EP1137774A2 (en) * | 1998-12-09 | 2001-10-04 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
KR20080067719A (ko) * | 2000-12-22 | 2008-07-21 | 제넨테크, 인크. | Gdnf 리간드 족의 구성원인 아르테민의 신규 용도 |
ES2289091T3 (es) * | 2001-02-01 | 2008-02-01 | Biogen Idec Ma Inc. | Conjugados polimeros de neublastina y metodos para usar los mismos. |
JP4499362B2 (ja) * | 2001-03-28 | 2010-07-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ニューロパシーの疼痛を処置するためのニューブラスチンポリペプチドの使用 |
RS52910B (en) * | 2003-01-31 | 2014-02-28 | Biogen Idec Ma Inc. | POLYMER CONJUGATES OF MUTATED NEUBLASTINE |
EP2322205A1 (en) * | 2003-04-18 | 2011-05-18 | Biogen Idec MA Inc. | Polymer-conjugated glycosylated neublastin |
-
2004
- 2004-02-02 RS YU20050585A patent/RS52910B/en unknown
- 2004-02-02 CN CNA200480009133XA patent/CN101166753A/zh active Pending
- 2004-02-02 SI SI200432136T patent/SI2246362T1/sl unknown
- 2004-02-02 ME MEP-438/08A patent/MEP43808A/xx unknown
- 2004-02-02 GE GEAP200411544A patent/GEP20135982B/en unknown
- 2004-02-02 EA EA200501212A patent/EA008743B1/ru not_active IP Right Cessation
- 2004-02-02 GE GEAP20048957A patent/GEP20084464B/en unknown
- 2004-02-02 MX MXPA05008168A patent/MXPA05008168A/es active IP Right Grant
- 2004-02-02 PT PT04707363T patent/PT1594436E/pt unknown
- 2004-02-02 EP EP10181704A patent/EP2301960A3/en not_active Withdrawn
- 2004-02-02 ES ES10173737.7T patent/ES2450115T3/es not_active Expired - Lifetime
- 2004-02-02 AT AT04707363T patent/ATE478891T1/de active
- 2004-02-02 NZ NZ541921A patent/NZ541921A/en not_active IP Right Cessation
- 2004-02-02 PT PT101737377T patent/PT2246362E/pt unknown
- 2004-02-02 GE GEAP200410236A patent/GEP20115137B/en unknown
- 2004-02-02 BR BRPI0407170-0A patent/BRPI0407170A/pt not_active IP Right Cessation
- 2004-02-02 CN CN201110239061.XA patent/CN102367277B/zh not_active Expired - Fee Related
- 2004-02-02 PL PL383683A patent/PL383683A1/pl unknown
- 2004-02-02 SI SI200431548T patent/SI1594436T1/sl unknown
- 2004-02-02 DE DE602004028801T patent/DE602004028801D1/de not_active Expired - Lifetime
- 2004-02-02 NZ NZ581460A patent/NZ581460A/en not_active IP Right Cessation
- 2004-02-02 EP EP10173737.7A patent/EP2246362B1/en not_active Expired - Lifetime
- 2004-02-02 UA UAA200508412A patent/UA91178C2/ru unknown
- 2004-02-02 KR KR1020057014050A patent/KR101216331B1/ko not_active IP Right Cessation
- 2004-02-02 DK DK04707363.0T patent/DK1594436T3/da active
- 2004-02-02 UA UAA200912089A patent/UA105892C2/uk unknown
- 2004-02-02 EP EP04707363A patent/EP1594436B1/en not_active Expired - Lifetime
- 2004-02-02 DK DK10173737.7T patent/DK2246362T3/en active
- 2004-02-02 AU AU2004209966A patent/AU2004209966B9/en not_active Ceased
- 2004-02-02 ES ES04707363T patent/ES2351215T3/es not_active Expired - Lifetime
- 2004-02-02 JP JP2006503213A patent/JP4742025B2/ja not_active Expired - Fee Related
- 2004-02-02 KR KR1020127021783A patent/KR101293805B1/ko not_active IP Right Cessation
- 2004-02-02 CA CA2514510A patent/CA2514510C/en not_active Expired - Fee Related
-
2005
- 2005-07-12 IS IS7938A patent/IS7938A/is unknown
- 2005-07-15 ZA ZA200505707A patent/ZA200505707B/en unknown
- 2005-07-28 IL IL169945A patent/IL169945A/en not_active IP Right Cessation
- 2005-08-30 NO NO20054025A patent/NO20054025L/no not_active Application Discontinuation
-
2006
- 2006-05-16 HK HK06105655.9A patent/HK1085663A1/xx not_active IP Right Cessation
-
2010
- 2010-03-24 JP JP2010069011A patent/JP2010184924A/ja not_active Withdrawn
- 2010-11-23 CY CY20101101050T patent/CY1111196T1/el unknown
-
2011
- 2011-01-17 JP JP2011007339A patent/JP2011078434A/ja not_active Withdrawn
-
2013
- 2013-08-01 IL IL227752A patent/IL227752A0/en unknown
-
2014
- 2014-03-13 CY CY20141100203T patent/CY1115085T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY151184A (en) | A polypeptide complex comprising non-peptidyl polymer having three functional ends | |
DE60333776D1 (de) | Pharmazeutische und kosmetische zubereitungen | |
PL369741A1 (en) | Immunocytokines with modulated selectivity | |
MEP43808A (en) | Polymer conjugates of mutated neublastin | |
RS51292B (sr) | Nova farmaceutska smeša | |
ATE430558T1 (de) | Herstellung von mikrokügelchen | |
CY1106886T1 (el) | Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων | |
TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
FR2632519B1 (fr) | Composition parfumante, a phase aqueuse continue, ayant une forte concentration en parfum | |
SV2004001294A (es) | Derivados de acido acetico ref. lea 35699-sv | |
ATE433759T1 (de) | Polymerkonjugiertes glycosiliertes neublastin | |
BR0108056A (pt) | Preparados cosméticos com extratos waltheria indica | |
Glocker et al. | Selective biochemical modification of functional residues in recombinant human macrophage colony-stimulating factor β (rhM-CSF β): identification by mass spectrometry | |
IS5998A (is) | Notkun mótefna til bólusetningar gegn krabbameini | |
ATE223701T1 (de) | Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen | |
ATE344223T1 (de) | Vitamin d-analoge | |
NO20044901L (no) | Anvendelse av modifiserte novirhabdoviruser i vaksiner | |
BR0113579A (pt) | Proteìnas sintéticas modificadas por polìmero | |
EA200600939A1 (ru) | Фармацевтический препарат, содержащий габапентин | |
BR8101417U (pt) | Banquinho portátil | |
DE60315069D1 (de) | Alkylsulfanylbenzole als duftstoffe | |
TR200301731U (tr) | Mobilya | |
ATE330671T1 (de) | Verwendung von alkyl 3-(n- alkylacetamino)propionat derivaten als feuchthaltemittel | |
CY1114475T1 (el) | Τροποποιημενη ανθρωπινη θυμικη λεμφοποιητινη | |
BR8202981U (pt) | Disposição construtiva aplicada à cadeira |